{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:40:10Z","timestamp":1758973210878,"version":"3.44.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.annder.2023.03.010","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T08:12:36Z","timestamp":1687853556000},"page":"281-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dual efficacy of upadacitinib in a patient with concomitant severe atopic dermatitis and alopecia areata"],"prefix":"10.1016","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3678-9635","authenticated-orcid":false,"given":"B.","family":"Walls","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Reguiai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2023.03.010_b0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","article-title":"Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review","volume":"85","author":"Toussi","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2023.03.010_b0010","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","article-title":"Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis","volume":"151","author":"Mohan","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2023.03.010_b0015","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2023.03.010_b0020","first-page":"1","article-title":"Two-sided influence of dupilumab on alopecia areata co-existing with severe atopic dermatitis: A case series and literature review","volume":"00","author":"Fukuyama","year":"2022","journal-title":"J Cutan Immunol Allergy"},{"key":"10.1016\/j.annder.2023.03.010_b0025","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2023.03.010_b0030","doi-asserted-by":"crossref","first-page":"e0164080","DOI":"10.1371\/journal.pone.0164080","article-title":"JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases","volume":"11","author":"Alves de Medeiros","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.annder.2023.03.010_b0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.annder.2022.03.006","article-title":"Alopecia areata: Recent advances and emerging therapies","volume":"149","author":"Seneschal","year":"2022","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2023.03.010_b0040","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2023.03.010_b0045","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1097\/DER.0000000000000780","article-title":"Dual efficacy of upadacitinib in 2 patients with concomitant severe atopic dermatitis and alopecia areata","volume":"32","author":"Gambardella","year":"2021","journal-title":"Dermatitis"},{"key":"10.1016\/j.annder.2023.03.010_b0050","doi-asserted-by":"crossref","first-page":"e15346","DOI":"10.1111\/dth.15346","article-title":"Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report","volume":"35","author":"Cantelli","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.annder.2023.03.010_b0055","doi-asserted-by":"crossref","DOI":"10.1111\/ijd.16316","article-title":"Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib","author":"Asfour","year":"2022","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.annder.2023.03.010_b0060","unstructured":"European Medicines Agency (EMA). EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. 28 October 2022. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic. Accessed Jan 01, 2023."}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963823000418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963823000418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:10:54Z","timestamp":1758971454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963823000418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0151963823000418"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2023.03.010","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual efficacy of upadacitinib in a patient with concomitant severe atopic dermatitis and alopecia areata","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2023.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}